Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XDx, a molecular diagnostics company, has signed a collaboration and license agreement with Laboratory Corporation of America Holdings (LabCorp) to develop Lupus Flare Predictor test.
Subscribe to our email newsletter
The companies will collaborate in marker discovery and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). Financial terms of the agreement have been kept confidential.
XDx president and chief executive officer Pierre Cassigneul said that the company has developed a database of lupus blood samples that it will use in collaboration with LabCorp to initiate its development of a biomarker for the flare test.
LabCorp chief medical officer Mark Brecher said, "Lupus remains a critical area of unmet medical need, and new tests are needed to help clinicians anticipate when patients may need additional therapeutic interventions for the treatment of flares."
XDx’s autoimmune diagnostics research and discovery experience and SLE blood sample database is combined with LabCorp’s diagnostic development and commercialization resources to advance the collaboration.